PHAXIAM Therapeutics SA (PHXM) Stock Price & Overview
NASDAQ:PHXM • US29604W2070
Current stock price
The current stock price of PHXM is 3.1 USD. Today PHXM is down by -0.64%. In the past month the price decreased by -29.55%.
PHXM Key Statistics
- Market Cap
- 18.832M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.04
- Dividend Yield
- N/A
PHXM Stock Performance
PHXM Stock Chart
PHXM Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PHXM.
PHXM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHXM. PHXM has a bad profitability rating. Also its financial health evaluation is rather negative.
PHXM Earnings
PHXM Forecast & Estimates
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
For the next year, analysts expect an EPS growth of 77.73% and a revenue growth -100% for PHXM
PHXM Groups
Sector & Classification
PHXM Financial Highlights
Over the last trailing twelve months PHXM reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 99.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.35% | ||
| ROE | -0.62% | ||
| Debt/Equity | 0.3 |
PHXM Ownership
PHXM Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.85 | 360.314B | ||
| AMGN | AMGEN INC | 15.12 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.09 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.53 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.98 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.85 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.61 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.68 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHXM
Company Profile
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Company Info
IPO: 2013-05-07
PHAXIAM Therapeutics SA
60 avenue Rockefeller
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 49
Phone: 33478744438
PHAXIAM Therapeutics SA / PHXM FAQ
What does PHXM do?
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
What is the stock price of PHAXIAM Therapeutics SA today?
The current stock price of PHXM is 3.1 USD. The price decreased by -0.64% in the last trading session.
Does PHAXIAM Therapeutics SA pay dividends?
PHXM does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHXM stock?
PHXM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting PHXM stock to perform?
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
Can you provide the market cap for PHAXIAM Therapeutics SA?
PHAXIAM Therapeutics SA (PHXM) has a market capitalization of 18.83M USD. This makes PHXM a Nano Cap stock.
Who owns PHAXIAM Therapeutics SA?
You can find the ownership structure of PHAXIAM Therapeutics SA (PHXM) on the Ownership tab.